Our findings suggest that instead of introducing IDH mutations into astrocytes [71, 78–80] or neural stem/progenitor cells [81–83] with proliferative advantages as the main readout, introducing IDH mutations into the context of oligodendrocyte lineage differentiation could be more advantageous for understanding of the pathogenesis and vulnerabilities of IDH-mutant gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.